Nicola Lucio Liberato

Statistics

Publications

Citations

530

H-Index

Active since

1999

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

University of Pavia

Azienda Sanitaria Locale di Asti

Mario Negri Institute for Pharmacological Research

Azienda Socio Sanitaria Territoriale di Pavia

Nicola Lucio Liberato is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in cost-effectiveness analysis, cost-effectiveness, and medicine.

Publications per year

1999–2023

Publications

Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Nicola Lucio Liberato, Monia Marchetti, Giovanni Barosi · Journal of Clinical Oncology · 2007 · 140 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Maria Carmela Piccirillo, Paolo A. Ascierto, Carlo Salvarani et al. · Journal of Translational Medicine · 2020 · 112 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis

Carla Rognoni, Monia Marchetti, Silvana Quaglini et al. · Clinical Drug Investigation · 2013 · 64 citations

Medicine, Cardiology, Pharmacotherapy +13

Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease

Monia Marchetti, Nicola Lucio Liberato, Antonio Di Sabatino et al. · The European Journal of Health Economics · 2012 · 49 citations

Pharmacy, Clinical Sciences, Pharmacoeconomics +15

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis

Carla Rognoni, Monia Marchetti, Silvana Quaglini et al. · Journal of Thrombosis and Thrombolysis · 2014 · 36 citations

Medicine, Cardiology, Pharmacotherapy +15

1–5 of 10